Genetics and immunogenetic aspects of primary pulmonary hypertension.

Primary pulmonary hypertension (PPH), also referred to as unexplained or idiopathic pulmonary hypertension, is the clinical term used to describe a condition in patients for which we can find no underlying cause. Patients with PPH not uncommonly also have evidence of immune dysregulation: autoimmune disorders, drug therapy, or HIV infections. We will review these associations and possible relevant abnormalities in immune regulation with regard to how they may play a role in the pathogenesis of PPH. Autoantibody-HLA correlations have been observed in several subsets of PPH patients. In addition, a familial form of PPH has been described and characterized with linkage to chromosome 2q31-q32. The identification of a specific gene for PPH and the subsequent understanding of its effects will help us identify the basic cause of PPH. Furthering our understanding regarding the role(s) and significance of immunogenetic as well as genetic aspects of the pathogenesis and pathophysiology of PPH should also lead to improved therapeutic modalities for PPH.

[1]  R. Barst,et al.  Detection of familial primary pulmonary hypertension by genetic testing. , 1997, The New England journal of medicine.

[2]  S. Hodge,et al.  Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. , 1997, Circulation.

[3]  N. D. Arnold,et al.  Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31–32 , 1997, Nature Genetics.

[4]  R. Barst,et al.  Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7. , 1997, American journal of respiratory and critical care medicine.

[5]  R. Barst,et al.  Primary pulmonary hypertension: immunogenetic response to high‐mobility group (HMG) proteins and histone , 1996, Clinical and experimental immunology.

[6]  J Benichou,et al.  Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. , 1996, The New England journal of medicine.

[7]  M. Fritzler,et al.  Review : Antibodies to fibrin-bound tissue-type plasminogen activator in systemic lupus erythematosus are associated with Raynaud's phenomenon and thrombosis , 1996, Lupus.

[8]  G. Sinha,et al.  Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles. , 1996, American journal of respiratory and critical care medicine.

[9]  K. Cooney,et al.  Familial association of primary pulmonary hypertension and a new low-oxygen affinity beta-chain hemoglobinopathy, Hb Washtenaw. , 1996, Chest.

[10]  D. Hart,et al.  Antibodies to fibrin bound tissue type plasminogen activator in systemic sclerosis. , 1995, The Journal of rheumatology.

[11]  A Giaid,et al.  Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. , 1995, The New England journal of medicine.

[12]  T. Foroud,et al.  Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. , 1995, American journal of respiratory and critical care medicine.

[13]  G. Simonneau,et al.  Continuous Infusion of Prostacyclin Decreases Plasma Levels of t-PA and PAI-1 in Primary Pulmonary Hypertension , 1995, Thrombosis and Haemostasis.

[14]  R. Redberg,et al.  Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. , 1995, American heart journal.

[15]  A. Theofilopoulos.  The basis of autoimmunity: Part II. Genetic predisposition. , 1995, Immunology today.

[16]  M. Fritzler,et al.  Antibodies to high mobility group proteins in systemic sclerosis. , 1994, The Journal of rheumatology.

[17]  C Lenfant,et al.  NHLBI funding policies. Enhancing stability, predictability, and cost control. , 1994, Circulation.

[18]  G. Simonneau,et al.  Markers of endothelial involvement in chronic pulmonary hypertension , 1994 .

[19]  M. Fritzler,et al.  Antibodies to HMG proteins in patients with drug-induced autoimmunity. , 1994, Arthritis and rheumatism.

[20]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[21]  F. Arnett,et al.  Autoantibodies in patients with primary pulmonary hypertension: association with anti-Ku. , 1992, The American journal of medicine.

[22]  D. Gladman,et al.  HLA alleles in systemic sclerosis: association with pulmonary hypertension and outcome. , 1992, British journal of rheumatology.

[23]  B. Groves,et al.  An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.

[24]  R. Barst,et al.  Familial pulmonary hypertension: immunogenetic findings in four Caucasian kindreds. , 1992, The American review of respiratory disease.

[25]  M. Bustin,et al.  Autoantibodies to the chromosomal protein HMG-17 in juvenile rheumatoid arthritis. , 1992, Arthritis and rheumatism.

[26]  R. Barst,et al.  Evidence for the Association of Unexplained Pulmonary Hypertension in Children With the Major Histocompatibility Complex , 1992, Circulation.

[27]  J. Sutcliffe,et al.  Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox , 1991, Cell.

[28]  J. Sutcliffe,et al.  Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome , 1991, Cell.

[29]  S. Rich,et al.  Familial pulmonary hypertension in association with an abnormal hemoglobin. Insights into the pathogenesis of primary pulmonary hypertension. , 1991, Chest.

[30]  J. Launay,et al.  Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin. , 1990, The American journal of medicine.

[31]  R. Virmani,et al.  Heterogeneity of pathologic lesions in familial primary pulmonary hypertension. , 1988, The American review of respiratory disease.

[32]  J. Rouleau,et al.  Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. , 1988, Annals of internal medicine.

[33]  E H Bergofsky,et al.  Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.

[34]  B. Brundage,et al.  Antinuclear antibodies in primary pulmonary hypertension. , 1986, Journal of the American College of Cardiology.

[35]  T. Medsger,et al.  Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. , 1986, Arthritis and rheumatism.

[36]  G. Hughes,et al.  Rheumatoid arthritis and pulmonary hypertension. A report of three cases. , 1985, The Journal of rheumatology.

[37]  F. Graziano,et al.  Pulmonary hypertension in a patient with mixed connective tissue disease: clinical and pathologic findings, and review of literature. , 1983, Clinical and experimental rheumatology.

[38]  L. Reid,et al.  Pulmonary veno-occlusive disease in siblings: case reports and morphometric study. , 1982, Human Pathology.

[39]  R. Tubbs,et al.  Fibrinolysis in familial pulmonary hypertension. , 1979, American journal of clinical pathology.

[40]  J. R. Kuipers,et al.  Familial pulmonary veno-occlusive disease: a case report. , 1977, Thorax.

[41]  D. S. Gordon,et al.  Abnormal fibrinolysis in familial pulmonary hypertension. , 1973, The American journal of medicine.

[42]  J. Aitchison,et al.  PULMONARY HYPERTENSION IN DERMATOMYOSITIS , 1956, British heart journal.

[43]  D. Dresdale,et al.  Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. , 1954, Bulletin of the New York Academy of Medicine.

[44]  D. Dresdale,et al.  Primary pulmonary hypertension. I. Clinical and hemodynamic study. , 1951, The American journal of medicine.